Antithrombotic treatment and major adverse cardiac events after bleeding in patients with myocardial infarction:a retrospective analysis of nationwide registry data by Nabi, Hafsah et al.
 
  
 
Aalborg Universitet
Antithrombotic treatment and major adverse cardiac events after bleeding in patients
with myocardial infarction
a retrospective analysis of nationwide registry data
Nabi, Hafsah; Rørth, Rasmus; Tajchman Mb, Daniel H; Holmvang, Lene; Torp-Pedersen,
Christian; Gislason, Gunnar; Fosbøl, Emil L; Køber, Lars; Sørensen, Rikke
Published in:
European heart journal. Cardiovascular pharmacotherapy
DOI (link to publication from Publisher):
10.1093/ehjcvp/pvz025
Publication date:
2020
Document Version
Accepted author manuscript, peer reviewed version
Link to publication from Aalborg University
Citation for published version (APA):
Nabi, H., Rørth, R., Tajchman Mb, D. H., Holmvang, L., Torp-Pedersen, C., Gislason, G., Fosbøl, E. L., Køber,
L., & Sørensen, R. (2020). Antithrombotic treatment and major adverse cardiac events after bleeding in patients
with myocardial infarction: a retrospective analysis of nationwide registry data. European heart journal.
Cardiovascular pharmacotherapy, 6(1), 14-21. https://doi.org/10.1093/ehjcvp/pvz025
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
1 
Antithrombotic treatment and major adverse cardiac events after bleeding in patients with myocardial 
infarction: a retrospective analysis of nationwide registry data 
Authors: Hafsah Nabi MB1; Rasmus Rørth MD1; Daniel H. Tajchman MB1; Lene Holmvang MD, DMSc1; 
Christian Torp-Pedersen, MD, DMSc2,3; Gunnar Gislason, MD, PhD4,5,6; Emil L. Fosbøl MD, PhD1; Lars Køber 
MD, DMSc1; Rikke Sørensen MD, PhD1;  
1Department of Cardiology, Copenhagen University hospital Rigshospitalet, Copenhagen, Denmark. 
2Department of Cardiology and Epidemiology/Biostatistics, Aalborg University Hospital, Denmark; 
3Department of Health Science and Technology, Aalborg University, Aalborg, Denmark 
4Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte, Hellerup, Denmark 
5The Danish Heart Foundation, Copenhagen, Denmark 
6The National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark 
Correspondence to: 
Rikke Sørensen, Blegdamsvej 9, 2100 Copenhagen, Denmark 
Tel. +45 23962884 
Mail: rikke.soerensen@regionh.dk 
         
© Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2019. 
For permissions, please email: journals.permissions@oup.com 
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz025/5528535 by Aalborg U
niversity Library user on 11 July 2019
This is a pre-copyedited, author-produced version of an article accepted for publication in European Heart Journal - Cardiovascular Pharmacotherapy following 
peer review. The version of record Hafsah Nabi, Rasmus Rørth, Daniel H Tajchman, Lene Holmvang, Christian Torp-Pedersen, Gunnar Gislason, Emil L Fosbøl, 
Lars Køber, Rikke Sørensen, Antithrombotic treatment and major adverse cardiac events after bleeding in patients with myocardial infarction: a retrospective 
analysis of nationwide registry data, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 1, January 2020, Pages 14–21is available online 
at: https://doi.org/10.1093/ehjcvp/pvz025 
2 
 
Abstract  
 
Aims: The aim of this study was to describe the use of antithrombotic therapy following a bleeding event 
among patients with myocardial infarction (MI), and the associated risk of major adverse cardiac events 
(MACE).  
 
Methods and Results: Using Danish nationwide registries patients hospitalized with a bleeding event within 
1 year after MI were identified. Antithrombotic treatment with aspirin, clopidogrel and/or vitamin K 
antagonists (VKA) was determined at the bleeding and at Day 90 and 180 post bleed. Based on guidelines, 
patients were stratified into four groups: expected, reduced, discontinued, or intensified treatment. Risk of 
MACE (ischemic stroke, MI, or death) within the first year was assessed by Cox proportional hazard models. 
A total of 3324 patients with a bleeding after MI were included. At day 90 post bleed 1052 (31.7%) received 
expected antitrombotic treatment, 1301 (39.2%) reduced, 164 (4.9%) intensified, and 807 (24.3%) no 
treatment. MACE occurred in 637 (19.2%) patients. With dual antiplatelet therapy (DAPT) as reference, 
adjusted hazard ratios for MACE were: aspirin 1.81 (1.06-3.09), clopidogrel 1.08 (0.64-1.82), VKA 1.08 (0.47-
2.48), VKA+aspirin 1.97 (0.95- 4.07), VKA+clopidogrel 0.26 (0.03-1.91), triple 1.73 (0.50-5.95), no treatment 
1.93 (1.11-3.36).  
Conclusions: The majority of MI patients reduced or discontinued their antithrombotic therapy post-bleed. 
Patients in monotherapy with aspirin or no treatment post-bleed had a higher risk of MACE Further studies 
of optimal antithrombotic treatments after a bleed are needed.  
 
Keywords: Myocardial infarction, bleeding, antithrombotic treatment 
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Introduction:   
Antithrombotic therapy is a cornerstone of treatment in patients with acute myocardial infarction (MI).(1, 2) 
Along with an early invasive strategy of coronary angiography and revascularization, antiplatelet 
treatments have reduced the incidence of recurrent thrombotic events and death.(3) However, many MI 
patients have additional indications for oral anticoagulation (OAC), i.e. atrial fibrillation or mechanical 
prosthetic heart valves,(3, 4) and combinations of antithrombotic drugs are widely used.(5, 6) In addition to the 
desired antithrombotic effect, antithrombotic pharmacotherapy is associated with an increased risk of 
bleeding, this risk is accentuated with the number of drugs used, and with certain combinations.(5) Several 
randomized trials have shown 30 days-risk of major bleeding of 1-8% among MI patients, whereas 
observational studies suggest an even higher bleeding rate up to 12%. (7-9) 
It is well established that patients who experience a bleeding have a higher risk of recurrent thrombotic 
events and death following the bleed.(10-13) Discontinuation of antithrombotic drugs leading to progressive 
recovery of platelet function and coagulation activity has been put forward as one of the underlying 
mechanisms. However, the clinical use of antithrombotic treatment in MI patients after a bleeding event is 
sparsely described. In addition, it is unknown, whether there is an association between antithrombotic 
treatment strategy post-bleed and the risk of recurrent thrombotic events and death.  
The purpose of this study was to describe antithrombotic treatment therapy after a bleeding event among 
MI patients and in addition to assess the associated risk of major adverse cardiac events (MACE). 
 
Methods: 
Data sources: 
This study was conducted by use of four nationwide registries, which were linked on an individual level by a 
unique personal identification number:  1) Danish National Patient Registry: contains information about all 
hospital admissions since 1978 and the associated discharge diagnoses according to the International 
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Classification of Diseases (ICD-8 and ICD-10) 2) The Danish Registry of Medicinal Product Statistics (The 
National Prescription Register): holds information about all claimed prescriptions since 1995. This includes 
information about date of dispensing, total quantity, strength and the international anatomical therapeutic 
chemical classification system (ATC) code. 3) The Danish Civil Registry: holds information on vital status, 
residency, migration and ancestry of each Danish citizen 4) The Danish Registry of Causes of Death: 
contains information on death since 1970.  
 
Ethics: 
Registry studies in which individuals cannot be identified do not require ethical approval in Denmark. This 
study was approved by the Danish Data Protection Agency (No. 2007-58-0015; internal reference: GEH 
2014-014, I-Suite no. 02732). 
 
Study population:  
By use of the Danish National Patient Registry, we identified patients aged 30 years or above who were 
hospitalized with first time MI (ICD-10 code I21 or I22) between the years 2000 and 2012.  We included 
those admitted with a bleeding event within the first year post-MI. Inclusion date was the day of hospital 
admission due to bleeding. A bleeding admission was defined as admission to hospital with a bleeding 
diagnosis (ICD-10 codes for bleeding diagnoses listed in appendix I). (14, 15) The period of one year was 
chosen as patients during this period are recommended intensified antithrombotic treatment. Patients, 
who were in no antithrombotic treatment at the bleeding event were excluded. No treatment was defined 
as no claimed prescriptions/no tablets available from previous claimed prescriptions. Furthermore patients, 
who died within 90 days post-bleed, were excluded to avoid immortal lifetime bias. (16) Flow chart is shown 
as Figure 1.  
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Comorbidity and pharmacotherapy: Hospitalizations within the year prior to the bleeding were used to 
define comorbidities according to the Modified Ontario acute myocardial infarction mortality prediction 
rules.(17) Because of low sensitivity of heart failure diagnoses, claimed prescriptions of loop diuretics within 
90 days before admission as a proxy for heart failure.(18) Patients with claimed prescriptions for glucose-
lowering agents were considered to have diabetes. Patients were classified by percutaneous coronary 
intervention (PCI), using the Danish procedure codes KFNG02 and KFNG05. Baseline pharmacotherapy 
(ACE-inhibitors, beta-blockers, antidiabetics, PPI, NSAIDs, loop diuretics, spironolactone and statins) was 
assessed, if a prescription was dispensed within 180 days prior to the bleeding event. Likewise, 
prescriptions of antithrombotics were used to assess antithrombotic treatment regimen.(5, 19) Because the 
inclusion period was from 2000-2012 only 5.4% of the MI patients received prasugrel/ticagrelor or NOAC 
after the MI and we chose to exclude these patients to uniform the population. 
 
Endpoints: 
The following endpoints were defined:  
1) Antithrombotic treatment at the following time points: at baseline, first claimed antithrombotic 
regimen within 90 days post-bleed, at day 90 and day 180 post-bleed.  
 
2) Claimed antithrombotic treatment versus expected treatment: 
Patients were classified in the following groups: expected treatment, reduced treatment, no 
treatment or intensified treatment. The ongoing antithrombotic treatment was evaluated at 
baseline, at the first claimed regimen post-bleed, at day 90 and day 180 post-bleed. 
 
The following criteria were used to define expected regimens: 
 Antiplatelet therapy: According to Guidelines 12 months treatment with dual antiplatelet 
therapy (DAPT) was expected after the MI diagnose. After 12 months, patients were 
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expected to be in lifelong monotherapy with aspirin or clopidogrel, unless they had an 
indication of OAC.(3, 20, 21) If the patient had an elective PCI within the first year post-MI, the 
DAPT period was extended 6 months after the date of PCI.(22) 
 Oral anticoagulation: Lifelong therapy of OAC was expected in patients with a diagnosis of 
mechanical heart valve, recurrent Pulmonary Embolism/Deep Venous Thrombosis (≥ 1 
event) and/or atrial fibrillation (AF) and CHA2DS2-VASc-score ≥ 1 at inclusion. In patients 
with first time pulmonary embolism or deep venous thrombosis, 6 months of OAC was 
expected. (diagnose codes and definition of CHA2DS2-VASc in Appendix I) 
 Combinations of antiplatelets and oral anticoagulation: OAC and DAPT was expected for 1 
year after the MI, if the indication of OAC was present at the MI diagnosis. If the indication 
of oral coagulation arose after the MI, or if it was temporary (first time PE/deep venous 
thrombosis) the expected period was adjusted accordingly.  
The following criteria were used to define reduced treatment: The patient was classified to 
have reduced treatment if he/she claimed less antithrombotic medication than expected 
(Supplementary Figure 2) and intensified treatment: The patient was classified to have 
intensified treatment if he/she claimed more antithrombotic medication than expected 
(Supplementary Figure 2). 
3) Associated risk of major adverse cardiac events (MACE): 
The associated risks of MACE were defined as recurrent MI, ischemic stroke or all-cause death, 
within the first year post-bleed, calculated from day 90 post-bleed. Definitions listed in the 
appendix.(23) Patients were censored at first event. 
Additional analyses:  
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz025/5528535 by Aalborg U
niversity Library user on 11 July 2019
7 
 
A sub-analysis of recurrent bleeding events was carried out, starting from day 90 post-bleed. A recurrent 
bleeding event was defined using the same ICD-10 discharge codes as at baseline (Appendix I). Patients 
were censored at first event. 
Furthermore, a sub-analysis of the patients with or without OAC at baseline and related outcomes were 
assessed.  
  
Statistical analyses:  
Categorical variables are presented in number and percentages, and continuous variables are presented 
with a mean/standard deviation or median/interquartile ranges. The antithrombotic treatments post bleed 
were assessed as first regimen within 90 days post-bleed, at Day 90 and Day 180 post-bleed. Sensitivity 
analyses on shorter intervals were tested (antithrombotic treatment at day 30 and day 60), but due to 
largely varying prescription lengths, we chose 90 days as the period. To assess the risk of MACE we used 
two different Cox Proportional Hazard Models. One included the antithrombotic drug exposure groups as 
time-varying covariates. Days where the patients were admitted was covered by medicine supplied by the 
hospital. With this model, patients were only considered at risk for each exposure group while taking the 
corresponding antithrombotic drug or were without treatment.  Each patient was allowed in one drug 
exposure group at a time; however it was possible to change exposure group based on claimed 
prescriptions, as done previously. (5, 19) The analyses were adjusted for relevant covariates as age groups, 
sex, comorbidity, concomitant medical therapy and PCI status. Due to non-linear distribution, age was 
included as age groups of <60 years, 60-70 years, 70-80 years and >80 years.  The second model included 
information of antithrombotic treatment after the bleeding categorized in following categories: no change, 
discontinued, reduced or intensified treatment. This model was adjusted for age groups, sex, comorbidity, 
concomitant medical therapy and PCI status.   The models were tested for absence of relevant interactions 
and found to be valid.  Results are presented as hazard ratios (HR) with 95% Confidence Intervals (CI).  
All statistical analyses were done using SAS version 9.4 (SAS institute Inc., Cary, NC, USA).  
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Results:                    
This study included 3324 patients with first-time myocardial infarction (MI), who were admitted with a 
bleeding event within one-year post-MI (Figure 1). Table 1 shows the baseline characteristics. Mean age 
was 71.2 (SD 11.5) for men and 75.4 (SD 11.4) for women.  
Antithrombotic treatment post-bleed: 
Mean time from bleeding to claimed prescription of antithrombotic treatment varied from 24.2 days (SD 
25.3) for triple therapy to 42.2 days (SD 26.8) for monotherapy with aspirin (Table 2). The majority of 
patients (78.8%) were in monotherapy with aspirin or clopidogrel or in no treatment within the first 90 days 
post bleed. Treatment patterns at day 90 and day 180 post-bleed are shown in Table 2. At day 180 post 
bleed, the largest group was in monotherapy with aspirin (33.0%) followed by DAPT (24.2%). Table 3 shows 
the proportion of patients in expected, reduced, intensified or no treatment. A discontinuation or reduction 
was observed in >70% of the patients after the bleeding event.  Baseline characteristics according to 
expected treatment are presented in the appendix, supplementary Table 1a, 1b and 1c. Comparing patients 
with or without OAC: Patients without OAC were more likely to be in expected treatment (at all time 
points), more discontinued treatment at first regimen and Days 90, whereas patients with OAC at all time 
points were more likely to received reduced or intensified treatment. Numbers are shown in Supplemental 
Table 3.   
  
Major adverse cardiac events (MACE): 
A total of 637 (19.2%) patients experienced MACE: 149 (4.5%) had a recurrent myocardial infarction, 73 
(2.1%) had a stroke and 415 (12.5%) died. Results from the Cox analyses are shown in Figure 2a+2b. 
Compared with DAPT, no antithrombotic treatment and monotherapy with aspirin were associated with an 
increased risk of major adverse cardiac events, the remaining antithrombotic exposure groups were not 
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significantly associated with an increased or decreased one-year risk of MACE. Other variables associated 
with increased risk of MACE were: increasing age, renal failure, heart failure, malignancy and use of proton 
pump inhibitors. In relation to expected treatment discontinuation was at all timepoints associated with 
increased risk of MACE. At Day 90 intensified treatment was also associated with increased risk of MACE, 
but not at first regimen or at Day 180. In the subgroup analysis of patients with OAC no treatment at Day 
90 was associated with a higher risk of MACE, as was both no and reduced treatment at Day 180.   
 
Recurrent bleeding events:  
A total of 431 (12.9%) patients had a recurrent bleeding event within one year. The distribution was 
following: urogenital bleeding event in 115 patients (3.5%), GI bleeding 108 patients (3.2%), anemia of 
acute or chronic bleeding 95 patients (2.8%), respiratory tract bleedings 88 patients (2.6%) and cerebral 
bleeding in 25 patients (0.8%). The Cox analyses did not show any significant associations between 
antithrombotic treatment regimen post-bleed and risk of recurrent bleeding events (supplementary 
appendix Table 1), expect in the subgroup of patients with OAC, where no treatment at first regimen and 
Day 90 was associated with a lower risk of bleeding.   
 
Discussion:  
This study is one of the first to describe the pattern of antithrombotic treatment after a bleeding event 
among patients with recent MI and the associated risk of major adverse cardiac events. The main findings 
are: 1. The majority of patients (79.7%) either discontinued or were reduced in their antithrombotic 
treatment within the first 90 days after the bleed. At day 90 and day 180 post-bleed, this number had 
declined, however more than 50% of the patients were still in no or reduced antithrombotic treatment. 2. 
We found that the risk of major adverse cardiac events (MACE) was significantly increased among patients, 
who were in no antithrombotic treatment or monotherapy with aspirin post-bleed. 3. We found no 
associations between the antithrombotic treatment post-bleed and risk of recurrent bleeding events.  
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Bleeding is a frequent complication among patients with acute coronary syndrome; up to 30% experience 
bleeding events of varying severity during the hospitalization.(11, 24, 25) Patients who bleed are in our and in 
other studies older and have more co-morbidities, including a history of prior stroke, heart failure, diabetes 
mellitus and PCI prior to the event. (8, 9) Previous studies have investigated the prognostic impact of 
bleeding episodes among patients with acute coronary syndrome, and have reported, that a major bleeding 
event was associated with a 5-fold increase in risk of death during the first 30 days. (10) The association was 
weaker between 30 days and 6 months, however mortality was still increased, and a similar pattern was 
seen for recurrent ischemic events (MI and stroke).(10) Another study by Rao et al. showed a stepwise 
increase in 30-day and 6 month mortality associated with increasing bleeding severity.(11) These findings 
have been supported by others.(8, 26, 27) Thus major bleeding is associated with a higher short- and long term 
mortality, and even minimal bleeding is of clinical significance.(26, 28) 
Lopes and colleagues reported a lower likelihood of receiving clopidogrel at discharge after an in-hospital 
bleeding among ACS patients treated with a PCI, whereas there was no significant difference in the use of 
aspirin.(9) In a study by Chan et al., discharge antithrombotic use was examined among 8582 ACS patients 
with in-hospital bleeding.(29) Almost 1 of 10 patients with bleeding was discharged without antiplatelets, 
and these patients had a higher risk of death, MI and stroke at six months, compared with patients 
receiving antiplatelets at discharge. This supports our findings, that absence of antithrombotic therapy 
post-bleed may contribute to the increased risk of ischemic events.(29) Wang et al. found differences in 
antiplatelet use after bleeding during index AMI hospitalization, a difference that persisted up to 6 months, 
but disappeared after one year.(30) Our results also indicate, that some patients resume their 
antithrombotic treatment within 6 months post-bleed.  
The Patterns of non-adherence to Antiplatelet Regimens in stented Patients (PARIS)-study investigated 
DAPT cessation among patients undergoing PCI. They found that approximately 3% had ceased DAPT within 
30 days and 20% within the first year after PCI. (31)The majority disrupted DAPT due to non-compliance or 
bleeding. Physician recommended cessation was associated with a lower risk of MACE, while no difference 
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was found among the group of temporary interruption due to surgical procedure. A disruption due to 
bleeding or non-compliance was associated with a higher risk of MACE.(31) 
Clearly, it is a clinical challenge to assess the risk and benefit of antithrombotic treatment after a bleeding 
event. Several studies have published recommendations on the acute management of bleeding; however 
less is known about the management of antithrombotic treatment after the bleeding event among MI 
patients. The European Society of Cardiology recently published a consensus paper, where it is 
recommended to consider resumption of antithrombotic drugs in patients with a clear indication, except if 
the bleeding is life-threatening.(32) Our findings support this approach as we found increased risk of MACE 
among patients receiving no treatment/or aspirin monotherapy post-bleed. Our study demonstrates that it 
is most common to reduce/or discontinue treatment after the bleeding event, and resume treatment after 
a period of time, a practice that is supported by the same consensus document.  
The patients that discontinued or reduced treatment were older, with more comorbidity as congestive 
heart failure, cerebrovascular disease, renal failure and atrial fibrillation compared with the patients in 
expected treatment. In addition, a lower number had been treated with PCI. Patients treated with OAC 
were likewise older with more comorbidity compared with those in dual antiplatelet therapy and were 
more likely to received reduced or intensified treatment at all time-point. This probably indicates a clinical 
dilemma where patients have both high risk of bleeding and thrombotic events.  At Day 90 we found that 
intensified treatment was also associated with increased risk of MACE, but not at other time points. The 
findings are in a small patient group and might be explained by patients initiating OAC due to atrial 
fibrillation and concurrent increased risk stroke.(4)  
 
Strengths and limitations: 
The main strength of our study is the completeness of data with a large nationwide unselected cohort of MI 
patients with complete information of prescriptions. However, our study has several limitations. We only 
included MI patients who were admitted for a bleeding and survived > 90 days, thus our population 
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represents a small proportion of an all-comer MI population and minor bleedings are not considered. Our 
data do not comprise reasons for prescription or cessation of medication, which is important in evaluation 
of the risk/benefit among different patient groups.  Also, the accuracy of the antithrombotic regimens post-
bleed is dependent on a prescription claim, and indirectly on the number of tablets from the previous 
prescription. If patients had claimed a large number of tablets before the bleeding, they would have a 
longer period until the next prescription but might have initiated treatment sooner, with tablets available 
from the previous purchase. We have implemented a 90-days period after bleeding to minimize this 
problem. The observational study design increases the risk of residual confounding, even after adjustment.  
At last, MACE was defined as admittance to a Danish hospital with recurrent MI, stroke or death. Those 
patients not admitted with MI or stroke/or admitted outside Denmark could not be classified, however the 
problem is considered minor, and data on vital status was complete in all patients. 
 
 
In conclusion, among patients with a bleeding post-MI, the majority reduced or discontinued 
antithrombotic therapy post-bleed. A higher risk of MACE was related to discontinuation of antithrombotic 
therapy or reduction to monotherapy with aspirin. Further studies of optimal antithrombotic treatments 
after a bleeding event are needed. 
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Figure Legends:  
Figure 1: Flowchart of patient selection 
Figure 2a+2b: Adjusted one-year risk of MACE in MI patients with a bleeding event Risk of within the first 
year post bleed. 
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Table 1. Baseline, according to anti-thrombotic treatment at bleeding event.  
                                                                                                             
   Monotherapy   Dual therapy  Triple therapy 
 All patients 
(n=3324) 
Aspirin 
(n=888) 
Clopidogrel 
(n=332) 
VKA 
(n=62) 
Aspirin+ 
Clopidogrel 
(n=1536) 
Aspirin+VKA 
(n=354) 
Clopidogrel+VKA 
(n=67) 
Aspirin+ 
Clopidogrel+VKA 
(n=85) 
Inclusion Year 
2000-2003 871 (26%) 453 (51%) 58 (18%) 22 (35%) 205 (13%) 120 (34%) 8 (12%) 5 (6%) 
2004-2006 970 (29%) 201 (23%) 113 (34%) 9 (15%) 503 (33%) 99 (28%) 22 (33%) 23 (27%) 
2007-2009 899 (27%) 139 (15%) 101 (30%) 14 (23%) 503 (33%) 91 (26%) 19 (28%) 32 (38%) 
2010-2012 584 (18%) 95 (11%) 60 (18%) 17 (27%) 325 (21%) 44 (12%) 18 (27%) 25 (29%) 
Demographics 
Men 2176 (65%) 542 (61%) 218 (66%) 39 (63%) 1037 (68%) 230 (65%) 49 (73%) 61 (71%) 
Age (men) Mean(SD)  
Median(IQR) 
     71.2 (11.5) 
72.2 (15.9) 
73.4 (11.9) 
75.1 (16.0) 
70.9 (11.8) 
72.4 (15.6) 
73.2 (12.2) 
74.9 (13.0) 
69.6 (11.6) 
70.3 (16.7) 
73.3 (9.4) 
74.9 (12.1) 
72.2 (6.9) 
71.6 (9.2) 
71.5 (9.4) 
73.0 (12.0) 
Age(women) Mean (SD) 
Median(IQR) 
75.4(11.4) 
77.3(14.6) 
77.9 (11.4) 
80.0 (15.2) 
76.2 (9.5) 
78.5 (11.9) 
76.0 (9.8) 
75.3 (11.3) 
73.2 (11.8) 
74.6 (16.6) 
75.6 (10.9) 
77.9 (13.4) 
75.9 (6.9) 
76.3 (11.9) 
79.5 (9.1) 
82.1 (11.3) 
Comorbidity 
Congestive heart failure 892 (27%) 261 (29%) 89 (27%) 20 (32%) 323 (21%) 131 (37%) 31 (46%) 37 (44%) 
Cerebrovascular Disease 374 (11%) 131 (15%) 36 (11%) 15 (24%) 125 (8%) 41 (12%) 15 (22%) 11 (13%) 
Diabetes with complication 318 (9%) 89 (10%) 40 (12%) 10 (16%) 124 (8%) 38 (11%) 7 (10%) 10 (12%) 
Atrial Fibrillation 1020 (31%) 247 (28%) 65 (20%) 47 (76%) 275 (18%) 273 (77%) 48 (72%) 65 (76%) 
Other cardiac dysrhythmias 268 (8%) 58 (7%) 14 (4%) 11 (18%) 106 (7%) 59 (17%) 8 (12%) 12 (14%) 
Recurrent VTE (>1) 51 (2%) 5 (1%) 6 (2%) 5 (8%) 14 (1%) 16 (5%) 1 (1%) 4 (5%) 
Acute renal failure 102 (3%) 36 (4%) 8 (2%) 3 (5%) 38 (3%) 14 (4%) 1 (1%) 2 (2%) 
Chronic renal failure 163 (5%) 55 (6%) 18 (5%) 4 (6%) 55 (4%) 21 (6%) 3 (4%) 7 (8%) 
Malignant disease 225 (7%) 73 (8%) 29 (9%) 3 (5%) 86 (6%) 30 (8%) 3 (4%) 1 (1%) 
Shock 27 (1%) 6 (1%) 2 (1%) 2 (3%) 11 (0.7%) 4 (1%) 1 (1%) 1 (1%) 
Pulmonary oedema 77 (2%) 34 (4%) 8 (2%) 3 (5%) 21(1%) 9 (3%) 2 (3%) 0 (0%) 
PCI 1437 (43%) 162 (18%) 171 (52%) 7 (11%) 920 (60%) 99 (28%) 34 (51%) 44 (52%) 
Pharmacotherapy 
ACEI 1948 (59%) 465 (52%) 211 (64%) 32 (52%) 880 (57%) 245 (69%) 55 (82%) 60 (71%) 
Anti-diabetics 468 (14%) 133 (15%) 56 (17%) 15 (24%) 178 (12%) 59 (17%) 13 (19%) 14 (16%) 
Beta-blocker 2639 (79%) 611 (69%) 278 (84%) 47 (76%) 1274 (83%) 294 (83%) 59 (88%) 76 (89%) 
Loop-diuretics 1439 (43%) 445 (50%) 142 (43%) 38 (61%) 496 (32%) 226 (64%) 43 (64%) 49 (58%) 
Spironolactone 395 (12%) 121 (14%) 34 (10%) 6 (10%) 129 (8%) 73 (21%) 19 (28%) 13 (15%) 
NSAID 669 (20%) 194 (22%) 63 (19%) 9 (15%) 328 (21%) 55 (16%) 9 (13%) 11 (13%) 
PPI 1090 (33%) 300 (34%) 120 (36%) 20 (32%) 490 (32%) 108 (31%) 24 (36%) 28 (33%) 
Statins 2497 (75%) 474 (53%) 280 (84%) 26 (42%) 1331 (87%) 255 (72%) 60 (90%) 71 (84%) 
First bleeding event 
Cerebral 132 (4%) 44 (5%) 10 (3%) 6 (10%) 54 (3%) 12 (3%) 3 (5%) 3 (4%) 
Gastrointestinal 925 (28%) 259 (29%) 88 (27%) 10 (16%) 441 (29%) 92 (26%) 12 (18%) 23 (27%) 
Respiratory tract 838 (25%) 144 (16%) 86 (26%) 26 (42%) 416 (27%) 111 (31%) 24 (36%) 31 (36%) 
Urogenital 720 (22%) 197 (22%) 78 (23%) 7 (11%) 352 (23%) 62 (18%) 11 (16%) 13 (15%) 
Anemia from acute or chronic bleeding 709 (21%) 244 (28%) 70 (21%) 13 (21%) 273 (18%) 77 (22%) 17 (25%) 15 (18%) 
Time from MI to bleeding in days 
Mean (SD 
Median (IQR) 
145 (104.6) 
124 (179.0) 
149(108.1) 
132 (187.5) 
165(99.4) 
156(160.5) 
158(103.5) 
150 (178.0) 
139 (104.0) 
110 (175.0) 
139 (105.3) 
115.0 (168.0) 
165 (97.5) 
154.0 (159.0) 
143 (93.3) 
112.0 (131.0) 
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Table 2:  Antithrombotic treatments post bleed 
 
 
 
 
 
 
 
 
 
*Time from bleeding event to prescription claim (days, mean [SD]) 
Aspirin: 42.2 ±26.8 (median 41) 
Clopidogrel 31.5 ± 24.3 (median 26) 
VKAs 34.4 ± 22.9 (median 32) 
Aspirin + Clopidogrel (DAPT) 35.8 ± 26.4 (median 32) 
Aspirin + VKA 34.7 ± 26.4 (median 31) 
Clopidogrel + VKA 29.2 ± 21.4 (median 26) 
Triple therapy 24.2 ± 25.3 (median 13) 
 
 
 
 
Antithrombotic regimen At the time 
of bleeding 
event 
(baseline) 
(n=3324) 
First 
antithrombotic 
regimen within 90 
days post bleed* 
(n=3324) 
Antithrombotic 
regimen day 90 
post bleed 
(n=3324) 
Antithrombotic 
regimen day 180 
post bleed 
(n=3123) 
None  736(22.1%) 807(24.3%) 567(18.2%) 
Aspirin 888(26.7%) 984(29.6%) 820(24.7%) 1031(33.0%) 
Clopidogrel 332(9.9%) 901(27.1%) 485(14.6%) 396(12.7%) 
VKAs 62(1.9%) 189(5.7%) 95(2.9%) 96(3.1%) 
Aspirin+Clopidogrel (DAPT) 1536(46.2%) 424(12.8%) 870(26.1%) 756(24.2%) 
Aspirin+VKA  354(10.7%) 54(1.6%) 129(3.9%) 176(5.6%) 
Clopidogrel+VKA 67(2.0%) 22(0.6%) 47(1.4%) 46(1.5%) 
Aspirin+Clopidogrel+VKA 85 (2.5%) 14(0.4%) 71(2.1%) 55(1.8%) 
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Table 3: Assessment of antithrombotic treatment post bleed 
 
 
 
 
 
 
 
 
 
 
 At the time of 
bleeding 
event 
(baseline) 
(n=3324) 
First regimen 
within 90 days 
post-bleed 
(n=3324) 
Day 90 post 
bleed 
(n=3324) 
Day 180 post 
bleed 
(n=3123) 
Expected treatment 1555(46.8%) 565(17.0%) 1052(31.7%) 1185 (37.9%) 
Discontinued 
treatment 
- 736(22.1%) 807(24.3%) 567(18.2%) 
Reduced treatment 1374(41.3%) 1914(57.6%) 1301(39.2%) 1089(34.9%) 
Intensified treatment 395(11.9%) 109(3.2%) 164(4.9%) 282(9.0%) 
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Patients (≥30years) registered with a first time MI between 
2000 and 2012
n=112851
A total of 108187 patients were excluded 
due to:
- Received ticagrelor/prasugrel/NOAC 
within the first year after MI (n=6079) 
Not meeting inclusion criteria of bleeding 
event after MI (n=93613)
- Not meeting inclusion criteria of bleeding 
event within a year after MI (n=8196)
- Lack of information about death (n=299)
4664 patients available for 
follow-up
A total of 1340 patients were excluded 
due to:
- No antithrombotic treatment at the time 
of bleeding event (n=543)
- Died 0-90 days after bleeding (n=797)
3324 patients available for 
follow-up
Figure 1: Flowchart of patient selection
Figure
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0,01 0,1 1 10
Hazard Ratio
Aspirin 
Clopidogrel
VKA
Aspirin+clopidogrel
VKA+aspirin
VKA+clopidogrel
Triple
No treatment
Hazard Ratio (CI)
1.81 (1.06-3.09)
1.08 (0.64-1.82)
1.08 (0.47-2.48)
Ref.
1.97 (0.95-4.07)
0.26 (0.03-1.91)
1.73 (0.50-5.95)
1.93 (1.11-3.36)
Risk of MACE (recurrent MI, ischemic stroke or death) related to different 
antithrombotic treatments within the first year post bleed *
*The Cox proportional Hazard model had the antitrombotic combinations included as time-dependent variables. The model was adjusted for age 
groups, sex, comorbidity, concomitant medical therapy and PCI status. 
Figure 2a
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0,1 1 10
Hazard Ratio
Intensified
Reduced
Discontinued
Expected
Intensified
Reduced
Discontinued
Expected
Intensified
Reduced
Discontinued
Expected
D
ay
 1
8
0
D
ay
 9
0
Fi
rs
t 
Risk of MACE (recurrent MI, ischemic stroke or death) related to expected treatment 
within the first year post bleed *
Hazard Ratio (CI)
1.14 (0.69-1.86)
1.07 (0.83-1.37)
1.40 (1.07-1.85)
Ref.
1.55 (1.06-2.28)
1.21 (0.98-1.50)
1.50 (1.20-1.88)
Ref.
1.29 (0.9-1.85)
1.18 (0.93-1.50
1.33 (1.03-1.74)
Ref.
*The Cox proportional Hazard model was adjusted for age groups, sex, comorbidity, concomitant medical therapy and PCI status.
Figure 2b
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